SS1(dsFV)PE38 Plus Pemetrexed and Cisplatin to Treat Malignant Pleural Mesothelioma
| Status: | Terminated |
|---|---|
| Conditions: | Lung Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - 100 |
| Updated: | 8/5/2018 |
| Start Date: | November 14, 2007 |
| End Date: | October 3, 2016 |
A Phase 1, Single Center, Dose-Escalation Study of SS1(dsFv)PE38 Administered Concurrently With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Epithelial Pleural Mesothelioma
Background:
Standard therapy for mesothelioma is a combination of the drugs pemetrexed and cisplatin.
However, the benefits of this treatment are limited, and in most treated patients the disease
continues to worsen.
SS1(dsFV)PE38 is a genetically engineered drug. It contains an antibody that binds to a
certain protein on mesothelioma cells and a toxin (type of poison) made from a product of a
bacterium called Pseudomonas aeruginosa. It is hoped that the antibody will attach to the
cancer cells, allowing the toxin to enter and kill the cells.
Objectives:
To find out if SS1(dsFV)PE38, together with pemetrexed and cisplatin is safe and tolerable in
patients with mesothelioma.
To determine the maximum tolerated dose of SS1(dsFV)PE38 (the highest dose that does not
cause unacceptable side effects).
To see if SS1(dsFV)PE38 given with pemetrexed and cisplatin has any effect on patients
tumors.
To learn how the body breaks down SS1(dsFV)PE38.
Eligibility:
Patients 18 years of age and older with epithelial pleural mesothelioma whose disease cannot
be cured with surgery, and have not had prior treatment with chemotherapy.
Design:
Treatment with pemetrexed, cisplatin and SS1(dsFV)PE38 in two 21-day cycles as follows:
- Day 1 - Intravenous (through a vein) infusions of pemetrexed and cisplatin.
- Days 1 and 2 - Intravenous solution to prevent dehydration that might occur with
SS1(dsFV)PE38.
- Days 1, 3 and 5 Intravenous infusion of SS1(dsFV)PE38. Small groups (3 to 6) of patients
are given SS1(dsFV)PE38 at a certain dose level. If the first group experiences no
significant side effects, the next group a higher dose. This continues in succeeding
groups until the maximum tolerated study dose (highest dose that patients can be given
safely) is determined.
Continuing standard treatment with additional cycles of pemetrexed and cisplatin.
Evaluations during the treatment period:
- Physical examination, including vital signs and body weight checks, and pregnancy test
for women who can become pregnant.
- Questions about medications and side effects.
- Blood and urine tests.
- Disease evaluation with CT, chest X-ray, and possibly PET scans, lung function tests,
pulse oximetry, performance of daily activities and quality-of-life questionnaires.
Post-treatment evaluations:
- Clinic visits at months 1, 3, 6, 12, 15, 18 and 21 for physical examination and disease
assessment.
- End-of-study visit for blood tests, vital signs and weight measurements, disease
assessment, electrocardiogram, pregnancy test for women who can become pregnant
Standard therapy for mesothelioma is a combination of the drugs pemetrexed and cisplatin.
However, the benefits of this treatment are limited, and in most treated patients the disease
continues to worsen.
SS1(dsFV)PE38 is a genetically engineered drug. It contains an antibody that binds to a
certain protein on mesothelioma cells and a toxin (type of poison) made from a product of a
bacterium called Pseudomonas aeruginosa. It is hoped that the antibody will attach to the
cancer cells, allowing the toxin to enter and kill the cells.
Objectives:
To find out if SS1(dsFV)PE38, together with pemetrexed and cisplatin is safe and tolerable in
patients with mesothelioma.
To determine the maximum tolerated dose of SS1(dsFV)PE38 (the highest dose that does not
cause unacceptable side effects).
To see if SS1(dsFV)PE38 given with pemetrexed and cisplatin has any effect on patients
tumors.
To learn how the body breaks down SS1(dsFV)PE38.
Eligibility:
Patients 18 years of age and older with epithelial pleural mesothelioma whose disease cannot
be cured with surgery, and have not had prior treatment with chemotherapy.
Design:
Treatment with pemetrexed, cisplatin and SS1(dsFV)PE38 in two 21-day cycles as follows:
- Day 1 - Intravenous (through a vein) infusions of pemetrexed and cisplatin.
- Days 1 and 2 - Intravenous solution to prevent dehydration that might occur with
SS1(dsFV)PE38.
- Days 1, 3 and 5 Intravenous infusion of SS1(dsFV)PE38. Small groups (3 to 6) of patients
are given SS1(dsFV)PE38 at a certain dose level. If the first group experiences no
significant side effects, the next group a higher dose. This continues in succeeding
groups until the maximum tolerated study dose (highest dose that patients can be given
safely) is determined.
Continuing standard treatment with additional cycles of pemetrexed and cisplatin.
Evaluations during the treatment period:
- Physical examination, including vital signs and body weight checks, and pregnancy test
for women who can become pregnant.
- Questions about medications and side effects.
- Blood and urine tests.
- Disease evaluation with CT, chest X-ray, and possibly PET scans, lung function tests,
pulse oximetry, performance of daily activities and quality-of-life questionnaires.
Post-treatment evaluations:
- Clinic visits at months 1, 3, 6, 12, 15, 18 and 21 for physical examination and disease
assessment.
- End-of-study visit for blood tests, vital signs and weight measurements, disease
assessment, electrocardiogram, pregnancy test for women who can become pregnant
Background:
SS1P (dsFv) PE38, is a recombinant immunotoxin targeting the tumor antigen mesothelin that is
highly expressed in malignant mesothelioma. The maximum tolerated dose (MTD) of SS1 dsFv has
been established in a phase I study.
Combination therapy with pemetrexed plus cisplatin is the standard first line therapy for
malignant mesothelioma, but results in a median overall survival of only 12.1 months.
Combination of SS1(dsFv)PE38 with pemetrexed plus cisplatin could result in improved outcomes
for patients with mesothelioma.
Objectives:
To determine the MTD of SS1(dsFv)PE38 that can be safely administered in combination with
pemetrexed plus cisplatin in patients with mesothelioma.
To characterize the toxicity profile of SS1(dsFv)PE38.
To study the pharmacokinetics of SS1(dsFv)PE388.
To observe anti-tumor activity, if any of SS1(dsFv)PE38 in combination with pemetrexed plus
cisplatin.
Eligibility:
Subjects with histologically confirmed epithelial pleural mesothelioma.
No prior radiotherapy (except palliative localized radiotherapy),systemic chemotherapy or
biologic therapy for pleural mesothelioma.
Design:
This is a phase I dose-escalation study of SS1(dsFv)PE38 in combination with pemetrexed plus
cisplatin.
The dose of pemetrexed plus cisplatin will be the standard dose approved for malignant
mesothelioma. The dose of SS1(dsFv)PE38 will be escalated to find the safe dose in
combination with pemetrexed plus cisplatin.
SS1(dsFv)PE38 will be administered concurrently with pemetrexed plus cisplatin in cycles one
and two, and subjects will receive additional cycles of pemetrexed and cisplatin as per
standard practice.
Patients will be assessed for response every 6 weeks.
An additional Single Cycle of SS1(dsFv)PE38 Cohort will involve up to 16 patients who will
receive SS1(dsFv)PE38 administered for four or five doses during the first cycle concurrently
with pemetrexed and cisplatin; subjects in this cohort will receive additional
cycles of pemetrexed and cisplatin as per standard practice
SS1P (dsFv) PE38, is a recombinant immunotoxin targeting the tumor antigen mesothelin that is
highly expressed in malignant mesothelioma. The maximum tolerated dose (MTD) of SS1 dsFv has
been established in a phase I study.
Combination therapy with pemetrexed plus cisplatin is the standard first line therapy for
malignant mesothelioma, but results in a median overall survival of only 12.1 months.
Combination of SS1(dsFv)PE38 with pemetrexed plus cisplatin could result in improved outcomes
for patients with mesothelioma.
Objectives:
To determine the MTD of SS1(dsFv)PE38 that can be safely administered in combination with
pemetrexed plus cisplatin in patients with mesothelioma.
To characterize the toxicity profile of SS1(dsFv)PE38.
To study the pharmacokinetics of SS1(dsFv)PE388.
To observe anti-tumor activity, if any of SS1(dsFv)PE38 in combination with pemetrexed plus
cisplatin.
Eligibility:
Subjects with histologically confirmed epithelial pleural mesothelioma.
No prior radiotherapy (except palliative localized radiotherapy),systemic chemotherapy or
biologic therapy for pleural mesothelioma.
Design:
This is a phase I dose-escalation study of SS1(dsFv)PE38 in combination with pemetrexed plus
cisplatin.
The dose of pemetrexed plus cisplatin will be the standard dose approved for malignant
mesothelioma. The dose of SS1(dsFv)PE38 will be escalated to find the safe dose in
combination with pemetrexed plus cisplatin.
SS1(dsFv)PE38 will be administered concurrently with pemetrexed plus cisplatin in cycles one
and two, and subjects will receive additional cycles of pemetrexed and cisplatin as per
standard practice.
Patients will be assessed for response every 6 weeks.
An additional Single Cycle of SS1(dsFv)PE38 Cohort will involve up to 16 patients who will
receive SS1(dsFv)PE38 administered for four or five doses during the first cycle concurrently
with pemetrexed and cisplatin; subjects in this cohort will receive additional
cycles of pemetrexed and cisplatin as per standard practice
- INCLUSION CRITERIA:
Subjects must meet all of the following criteria to be eligible to participate in the
study:
Subjects must have histologically confirmed epithelial or biphasic pleural mesothelioma not
amenable to potentially curative surgical resection. However, patients with biphasic tumors
that have a predominantly sarcomatoid component will be excluded.
Measurable disease
Subjects must be greater than or equal to 18 years old
Karnofsky Performance Status (KPS) of greater than or equal to 70
Life expectancy of greater than 3 months, as assessed by the principal investigator.
Adequate organ function with:Hepatic function: serum transaminases (either ALT or AST) or
bilirubin, less than or equal to Grade 1, unless due to cancer or Gilbert s disease; less
than or equal to Grade 2, if due to cancer
Renal function: serum creatinine clearance greater than or equal to 60mL/min as estimated
by Cockroft-Gault formula.
Bone marrow function: ANC of at least 1,500/mm (3), Platelet count at least 100,000/mm (3)
Pulmonary Function: FEV (1) greater than or equal to 50 percent of predicted value
(post-pleural drainage and bronchodilation if these are indicated)
Must be able to understand and sign informed consent
Female and male subjects agree to use an approved method of contraception during the study
EXCLUSION CRITERIA:
Subjects must not be pregnant or breast feeding
Prior radiotherapy (except palliative extra-thoracic localized radiotherapy) or biologic
therapy for malignant pleural mesothelioma within 4 weeks
Prior systemic chemotherapy for malignant pleural mesothelioma
Documented and ongoing central nervous system involvement with their malignant disease
(history of CNS involvement is not an exclusion criterion but the CNS metastases should
have been adequately treated (radiation or surgical resection) and subjects are free from
symptoms for 3 months off steroids).
Clinically significant heart disease (New York Heart Association Class III or IV)
Active bacterial or fungal infection.
Baseline coagulopathy greater than or equal to Grade 3 unless due to anticoagulant therapy
Surgery or pleurodesis within 2 weeks
HIV positive serology (due to increased risk of severe infection and unknown interaction of
SS1(dsFv)PE38 with antiretroviral drugs)
Hepatitis B surface antigen positivity
Subjects with other (non-mesothelioma) cancers who meet eligibility criteria and have had
less than 5 years of disease-free survival will be considered on a case-by-case basis
Uncontrolled, symptomatic, intercurrent illness including but not limited to: infections
requiring systemic antibiotics, unstable angina pectoris, cardiac arrhythmia, psychiatric
illness, or social situations that would limit compliance with study requirements.
We found this trial at
1
site
9000 Rockville Pike
Bethesda, Maryland 20892
Bethesda, Maryland 20892
Click here to add this to my saved trials
